Evaluation of the efficacy of mifepristone/misoprostol and methotrexate/misoprostol for medical abortion.
Indian J Med Sci
;
2005 Jul; 59(7): 301-6
Article
in English
| IMSEAR
| ID: sea-68111
ABSTRACT
BACKGROUND:
Unsafe abortion is a major cause of mortality among women in India accounting for 12% of all maternal deaths. In developing countries, annually, up to 200,000 women die of complications after illegal abortion. Medical abortion is potentially a simple and a safe method for use in developing countries. We conducted a prospective controlled trial to compare the efficacy of low-lose mifepristone and methotrexate for medical abortion.OBJECTIVE:
To find out the efficacy of low-dose mifepristone and methotrexate for inducing abortion.METHOD:
In this prospective clinical study, 100 women opted for a medical method of abortion. Out of these, 50 patients were given 50 mg/m2 of methotrexate intramuscularly followed by 800 micro gm of intravaginal misoprostol, and 50 patients were given 200 mg of mifepristone orally followed by 800 micro gm of intravaginal misoprostol. MAIN OUTCOMEMEASURES:
Complete abortion was the principal outcome measure. Secondary outcome measures were side effects and acceptability data.RESULTS:
The rate of expulsion by first week after initiation of treatment was 58% in methotrexate and 98% in mifepristone group (P <0.001).CONCLUSION:
Low-dose mifepristone and intravaginal misoprostol is safe, effective, and well tolerated as compared to methotrexate and misoprostol.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Female
/
Humans
/
Abortifacient Agents
/
Pregnancy
/
Chi-Square Distribution
/
Mifepristone
/
Methotrexate
/
Prospective Studies
/
Treatment Outcome
/
Misoprostol
Type of study:
Controlled clinical trial
/
Evaluation studies
/
Observational study
Language:
English
Journal:
Indian J Med Sci
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS